Skip to main content
Premium Trial:

Request an Annual Quote

Proscia, Ibex Medical Analytics Strike Prostate Cancer Diagnosis Partnership

NEW YORK — Digital pathology firm Proscia and Ibex Medical Analytics said on Thursday that they have agreed to combine their respective technologies into an integrated product for artificial intelligence-based prostate cancer diagnosis.

Under the terms of the alliance, the companies will join Proscia's Concentriq image and data management platform with Ibex's Galen Prostate system, which uses AI to help pathologists detect and grade prostate cancer in biopsies.

Proscia and Ibex said that they will begin to make Galen Prostate available to Concentriq users, beginning with select customers in the US and Europe. Additional terms of the deal were not disclosed.

"We are excited to partner with Proscia to accelerate development and rollout of end-to-end digital pathology solutions that utilize the full potential of our AI technology," Ibex Cofounder and CEO Joseph Mossel said in a statement.

In late 2020, Philadelphia-based Proscia raised $23 million in Series B funding. Earlier that year, Tel Aviv-based Ibex received CE-IVD marking for Galen Prostate.